Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
FACTORS INVOLVED IN CLINICAL-PHARMACOLOGY VARIABILITY IN ONCOLOGY
Autore:
CHABOT GG;
Indirizzi:
INST GUSTAVE ROUSSY,PHARMACOTOXICOL & PHARMACOGENET LAB,CNRS,URA 147,PAVILLON RECH 39 F-94805 VILLEJUIF FRANCE
Titolo Testata:
Anticancer research
fascicolo: 6A, volume: 14, anno: 1994,
pagine: 2269 - 2272
SICI:
0250-7005(1994)14:6A<2269:FIICVI>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
METABOLIZING ENZYME-SYSTEMS; CELL LUNG-CANCER; PERITUMORAL TISSUES; TUMOR-TISSUE; PHARMACOKINETICS; TOXICITY; BREAST; DOXORUBICIN; CISPLATIN; PLATINUM;
Keywords:
ANTICANCER DRUGS; PHARMACOLOGY; VARIABILITY; TOXICITY; TUMOR RESPONSE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
G.G. Chabot, "FACTORS INVOLVED IN CLINICAL-PHARMACOLOGY VARIABILITY IN ONCOLOGY", Anticancer research, 14(6A), 1994, pp. 2269-2272

Abstract

One of the major problems in cancer pharmacology is the prediction ofthe outcome of treatment in terms of both toxicity and tumor response. Indeed, why is a patient presenting a high toxicity at a standard dose? Also, why is another patient presenting a response to chemotherapy, while another does not respond, even if the same doses and drugs areused? The causes of variability in the response to chemotherapy can be classified in 2 classes, these related to the host, and those related to the tumor. Concerning the host, physiopathological parameters caninfluence the outcome of treatment e.g. age, sex, kidney and liver functions, plasma protein binding, concomitant treatments, and pharmacogenetics. With regard to the tumor, many factors can also influence chemotherapy e.g tumor type, localization, volume, aggressiveness, dissemination stage, prior treatments (resistance), biological marker levels, and pharmacogenetic phenotype. Although some progress has been made in the past years concerning the clinical use of some factors responsible for the variability of pharmacological response in oncology, much remains to be done in order to adapt the treatment to a particular patient. Although pharmacogenetic phenotyping has been feasible for some anticancer drugs, this area deserves more effort in the future. Indeed, pharmacogenetic phenotyping of both the patient and the tumor will probably allow to tailor chemotherapy to an individual patient, in order to optimize the patient's chances to obtain a tumor response with minimum systemic toxicity.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 22:26:56